Background: To establish the maximum tolerated dose, determine safety/tolerability and evaluate the pharmacokinetics and preliminary efficacy of olaparib in combination with cisplatin in patients with advanced solid tumors.
introduction Poly(ADP-ribose) polymerases (PARP) are essential for cellular processes involved in cell survival, including the repair of DNAstrand breaks. Small molecule inhibitors of PARP exert their antitumor activity by inhibiting the catalytic function of PARP when repairing single-strand breaks and by trapping the enzyme at damaged DNA [1, 2] . Persistence of single-strand breaks during the replication phase leads to double-strand breaks that cannot be repaired in tumors with homologous recombination deficiency [3, 4] , such as those with mutations in the tumor suppressor genes BRCA1 and BRCA2, a concept known as synthetic lethality [5] .
Olaparib is a potent oral PARP inhibitor, which has shown antitumor activity and an acceptable safety profile in phase II monotherapy studies in patients with BRCA1/2 mutations [6, 7] . More recently, olaparib as maintenance treatment significantly improved progression-free survival in patients with platinumsensitive, high-grade relapsed serous ovarian cancer with the greatest clinical benefit in patients with a BRCA1/2 mutation [8, 9] .
PARP inhibition has been suggested to enhance the antitumor activity of DNA-damaging chemotherapies and overcome acquired resistance to these agents [10] [11] [12] . The combination of olaparib with cisplatin has demonstrated synergistic cytotoxicity in BRCA2-deficient mammary cell lines [13] . In addition, in a genetically engineered mouse model of BRCA1-deficient mammary tumors, treatment with olaparib and a platinum drug (cisplatin or carboplatin) induced an increase in overall survival versus either agent alone [14] .
Previously, olaparib 400 mg twice daily (bid) in combination with chemotherapy in patients with advanced solid tumors has been reported to result in dose-limiting hematologic adverse events (AEs), including neutropenia and thrombocytopenia [15] [16] [17] .
The aim of this dose-finding study was to determine a tolerated dose and schedule for olaparib capsules in combination with cisplatin in patients with advanced breast, ovarian and other solid tumors (Clinicaltrials.gov identifier: NCT00782574).
materials and methods patients
Eligible patients were aged ≥18 years and had histologically confirmed metastatic cancer that was not amenable to surgery or radiation therapy; progressed on standard therapy; an Eastern Cooperative Oncology Group (ECOG) performance status ≤2; life expectancy of ≥12 weeks; and adequate hematologic, hepatic and renal function. All patients provided written informed consent.
study design
In this phase I, open-label, multicenter study, patients received bid oral olaparib (capsule formulation) continuously (days 1-21), in combination with cisplatin 75 mg/m 2 on day 1 of each 21-day treatment cycle (supplementary Figure S1 , available at Annals of Oncology online). If continuous olaparib dosing was not tolerated [the MTD was defined as the dose level below that in which ≥2 patients experienced a dose-limiting toxicity (DLT)], intermittent dosing regimens would be explored. A minimum of three assessable patients were assigned to each cohort; if one patient experienced a DLT, the cohort was expanded to ≥6 patients before olaparib dosing was increased. DLTs included the following study drug-related events occurring during cycle 1: grade 4 neutropenia lasting >5 days, grade 4 thrombocytopenia, febrile neutropenia, treatment delay of >2 weeks, any other grade 3 nonhematologic toxicities. Patients who completed six cycles of combination therapy could continue to receive olaparib plus cisplatin, provided they were benefiting; alternatively, patients who completed six cycles, or who permanently discontinued cisplatin owing to cisplatin-related toxicity, could continue to receive olaparib as monotherapy (at 400 mg bid) at the investigator's discretion. The study was carried out in accordance with the Declaration of Helsinki, Good Clinical Practice and the AstraZeneca policy on Bioethics [18] .
study end points and assessments
The primary objective was to determine the safety and tolerability of olaparib in combination with cisplatin and to define the MTD for this treatment combination. Secondary objectives were to compare the exposure of olaparib alone and in combination with cisplatin, and to assess the antitumor activity of olaparib in combination with cisplatin by objective response rate (ORR). AEs and laboratory parameters were recorded and graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (v3.0).
Blood samples were collected following administration of a single dose of olaparib to evaluate the pharmacokinetics (PK) of olaparib alone. protocol amendment, BRCA1/2 mutation status was collected for patients who had previously been tested for germline BRCA mutations.
statistical analysis
Safety and tolerability were assessed for all patients who received ≥1 dose of study medication. PK parameters were calculated for all patients receiving continuous olaparib dosing for whom PK data were reported. Plasma concentration-time data were analyzed using non-compartmental methods. No formal statistical analyses were carried out on safety, PK and efficacy data. Table 1 .
patient recruitment
The dose-escalation strategy is outlined in Table 2 . The first DLT (grade 3 neutropenia with dose delay) was noted in cohort 3, which was expanded to six patients. Subsequently, the dosing regimen in cohort 3 was deemed non-tolerable by the Safety Monitoring Committee (SMC) and the previous cohort was expanded. During the expansion phase of cohort 2, only 3 out of 10 patients were able to receive ≥4 treatment cycles. It became apparent that there were emerging toxicities in the first two cohorts during later treatment cycles and that it was inadequate to evaluate only one treatment cycle for a dose-escalation decision. Therefore, the study investigators agreed that three cycles at a given dose level would be assessed before dose escalation.
Following cohort 3, a dose-reduction rather than dose-escalation strategy was implemented due to hematologic toxicity issues, and intermittent dosing of olaparib was instigated. After cohort 4, the SMC decided to reduce olaparib dosing to days 1-5 of 21, and to start with four patients in subsequent cohorts. When the expanded cohort 5 was deemed non-tolerable by the SMC, data from previous cohorts showed improved tolerability in patients receiving an initial cisplatin dose of 75 mg/m 2 that was subsequently reduced to 60 mg/m 2 . Therefore, cohort 6 evaluated an initial dose of 60 mg/m 2 cisplatin in combination with a low dose of olaparib (50 mg bid, days 1-5).
treatment exposure and tolerability
The median actual exposure to olaparib was 114 days (16.3 weeks) and highly variable between cohorts [11 weeks (cohort 2)-163 weeks (cohort 1)]: patients in cohort 1 had the longest opportunity to remain on continuous treatment before data cutoff. Overall, 37 (69%) and 21 (39%) patients received ≥4 and ≥6 cycles of combination therapy, respectively. In cohort 6, nine (75%) and six (50%) patients received ≥4 and ≥6 cycles, respectively; this cohort had the highest cisplatin dose intensity percentage (median 95%, range 80%-100%).
Following cisplatin discontinuation, 29 patients (54%) received ≥1 dose of olaparib monotherapy. For these patients, the median duration of olaparib monotherapy received was 133 days (range 15-1014 days) and, at data cut-off, two patients remained on olaparib monotherapy after 31 and 36 months, respectively.
Thirty-nine patients (72%) had an olaparib dose interruption or reduction (supplementary Table S1 , available at Annals of Oncology online). In total, 31 patients (57.4%) experienced AEs that led to olaparib dose modification; 18 experienced hematologic AEs, including neutropenia (n = 14), leukopenia (n = 5), anemia (n = 3) and thrombocytopenia (n = 2). Overall, 41 (76%) patients had a cisplatin dose modification. As expected with a lower cisplatin starting dose (60 mg/m 2 ), cohort 6 had the fewest patients requiring cisplatin dose modifications (7/12 patients; 58%); three out of seven were grade 2 neutropenia that resolved with dose delay.
In total, four DLTs were recorded during the study: grade 3 neutropenia (cohort 3 and cohort 2 expansion, n = 1 each) and grade 3 lipase elevation (cohort 4 and cohort 5, n = 1 each). The most common AEs and grade ≥3 AEs are shown in Table 3 . Sixteen patients (29.6%) reported 27 serious AEs; of which, five were considered to be causally related to olaparib (nausea, vomiting, thrombocytopenia, migraine and dyspnea). There were no drug-related deaths during the study. Three AEs (5.6%) led to discontinuation of study treatment (cohort 2, thrombocytopenia; cohort 3, complex migraine and fatigue/ dyspnea). Across all cohorts, 24 AEs related to hematology laboratory parameters were reported in 14 patients (25.9%). Colony-stimulating factors were precluded from cycle 1, but were used for hematologic support in 30 (55.6%) patients after this cycle.
antitumor activity
The ORR for all patients with measurable disease at baseline was 41% (19/46 patients; supplementary Table S2 , available at Annals of Oncology online). The median (range) time to onset of response was 48 (35-172) days; of the patients who experienced an objective response and received olaparib monotherapy, all 15 achieved the response before starting monotherapy. Best percentage changes in target lesion size are shown in Figure 1 . There was no evidence that response rate varied by performance status, age or tumor type. In patients with breast and ovarian cancer who had a known BRCA1/2 mutation, the ORR was 71% (12/17 assessable patients) and 43% (3/7 assessable patients), respectively. The best response of the patient with pancreatic cancer was stable disease. By data cut-off (1 February 2012), 13% of patients with measurable disease at baseline (6/46) had achieved durable tumor responses (objective responses >1 year) with continued single-agent olaparib treatment; durable responses occurred in patients with both breast (n = 5) and ovarian (n = 1) cancer. Two responses lasted >3 years. Our study was based on a standard 3 + 3 design for dosefinding trials, with the initial dose of olaparib (50 mg bid continuously) based on the first-in-human phase I study of olaparib in patients with advanced solid tumors [19] . The initial dose of olaparib is closest to the lowest dose (60 mg bid) analyzed in the phase I trial that achieved more than 90% of PARP inhibition and that might be adequate to enhance the DNA damage caused by cisplatin. As a result of hematologic DLTs, the continuous olaparib schedules were considered non-tolerable and intermittent olaparib dosing was tested. Two DLTs, both grade 3 lipase elevation (a known toxicity of cisplatin), were observed with intermittent dosing in cohorts 4 and 5; both events were attributed to cisplatin and controlled with a reduction in cisplatin dose to 60 mg/m 2 . Since an initial aim of our study was to maintain the full standard dose of cisplatin (75 mg/m 2 ), the olaparib dose was initially reduced to manage hematologic toxicity. Nevertheless, it became apparent that even very low doses of olaparib administered intermittently were ineffective in overcoming the toxicities that resulted in dosing delays. Tolerability improved in cohort 6 with a lower dose of cisplatin (60 mg/m 2 ): this cohort required the fewest dose modifications and no patients reported grade 3 events related to hematologic toxicity.
In fact, cohort 6 demonstrated the highest cisplatin dose intensity (median 95.1%; range 80%-100%). Although the MTD was not established, we considered the schema of cisplatin 60 mg/m 2 with intermittent olaparib 50 mg bid to be tolerable. It might be that even this low dose of olaparib is adequate to chemosensitize tumor cells to cisplatin exposure by inhibition of PARP. The most common grade 3 AEs were hematologic, including the two DLTs of neutropenia. Hematologic DLTs have previously been reported when combining chemotherapy with olaparib [15] [16] [17] . In a recent, phase I study of olaparib with carboplatin [20] , the most common grade 3 AEs were also hematologic (neutropenia, 42%; thrombocytopenia, 20%; anemia, 13%) and were reported more frequently than in combination with cisplatin in our trial. In both studies, the tolerable schemas required decreasing the standard doses of carboplatin (AUC 5) and cisplatin (60 mg/m 2 ); however, higher intermittent doses of olaparib were considered tolerable when combined with carboplatin (400 mg bid, days 1-7). Unfortunately, our phase I study did not test whether cisplatin 60 mg/m 2 could be tolerable with higher doses of olaparib. Finally, the combination of carboplatin with paclitaxel (175 mg/m 2 ) required lowering the doses of carboplatin (AUC 4) and olaparib (200 mg bid, days 1-10) [21] , highlighting the overlapping hematologic toxicity observed when these drugs are combined.
In our phase I study, promising antitumor activity was observed in heavily pretreated patients with an ORR of 41% in the overall population. Indeed, the ORRs of 71% and 43% among breast and ovarian cancer patients, respectively, with a germline BRCA1/2 mutation were higher than those reported in previous phase II trials of olaparib monotherapy in patients with BRCA-mutated breast (0-41%) or ovarian (33-41%) cancer [6, 7, 22] . In the current study, BRCA1/2 mutation status data were collected retrospectively and are not centrally validated, so should be interpreted with caution; however, consistent with previous olaparib studies in monotherapy [22] , the response rate was higher for patients with a germline BRCA1/2 mutation than for those with no mutation (60% versus 8%). Although direct comparisons cannot be made, the 71% ORR that we observed in breast cancer patients with a BRCA1/2 mutation lies between that achieved in studies of cisplatin or carboplatin alone in patients with advanced breast cancer and a BRCA mutation (ORR 55%-80%) [23, 24] . A randomized threearm study could help to define whether a combination regimen (with cisplatin or carboplatin) improves clinical efficacy versus either agent alone. It would also be very interesting to test whether a sequential treatment of olaparib, after achieving a response with a platinum-based regimen, would improve duration of response compared with a combination schema.
In addition to the responses observed with combination therapy, durable responses were observed with continued olaparib monotherapy in patients with breast cancer. These findings suggest that olaparib might be a promising maintenance treatment following combination with chemotherapy, which is a strategy that has not yet been tested among patients with breast cancer and a germline BRCA1/2 mutation. Results from a randomized, placebo-controlled, phase II study of olaparib maintenance monotherapy in patients with platinum-sensitive relapsed, high-grade serous ovarian cancer showed a significant improvement in progression-free survival (P < 0.0001) compared with patients receiving placebo [8] ; the greatest clinical benefit was observed in patients with a BRCA1/2 mutation [9] , and these results have led to phase III trials which are currently ongoing. In summary, continuous or intermittent olaparib in combination with cisplatin 75 mg/m 2 was not considered tolerable, but the use of intermittent olaparib at minimum doses with a lower cisplatin dose improved tolerability. Evidence of antitumor activity was observed, particularly in patients with germline BRCA1/2 mutations. Finally, continuous olaparib monotherapy after combination treatment provided durable responses, especially among breast cancer patients. Therefore, olaparib might be investigated further as a maintenance therapy in this setting. 
